share_log
Reuters ·  Mar 18 11:00
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-a as Treatment for Obesity in Type 2 Diabetes Patients
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 326

Recommended

Write a comment